1995PubMedRequires access

Management of congestive heart failure in the elderly patient.

Wilbert S. Aronow

Open publisher page 0 citations

Abstract

Coronary artery disease, hypertension, valvular heart disease, and cardiomyopathies are the commonest causes of CHF in elderly patients. Almost half of elderly patients with CHF have normal LV ejection fraction. LV ejection fraction must be measured before knowing how to treat CHF. Underlying causes of CHF should be treated when possible. Precipitating causes of CHF should be treated. Diuretics are the first-line drug in the treatment of CHF. ACE inhibitors reduce mortality in patients with CHF and should be administered with diuretics to patients with CHF and abnormal or normal LV ejection fraction. Oral isosorbide dinitrate plus hydralazine improves survival in patients with CHF, and should be administered to patients with CHF and abnormal or normal LV ejection fraction who cannot tolerate ACE inhibitor therapy or in whom CHF persists despite therapy with diuretics plus ACE inhibitors. Digoxin should be administered to patients with a rapid ventricular rate associated with supraventricular tachyarrhythmias. Digoxin should be administered to patients with CHF in sinus rhythm and abnormal LV ejection fraction that does not respond to diuretics plus ACE inhibitors or in patients unable to tolerate ACE inhibitors or other vasodilator therapy. Digoxin should not be given to patients with CHF in sinus rhythm with normal LV ejection fraction. Calcium channel blockers are contraindicated in patients with CHF and abnormal LV ejection fraction but may be used to treat CHF with normal LV ejection fraction. The use of beta blockers in the treatment of CHF with abnormal LV ejection fraction is experimental. However, beta blockers might improve clinical symptoms in patients with CHF and normal LV ejection fraction by slowing heart rate, thereby increasing LV diastolic filling time and increasing LV end-diastolic volume. Maintenance of sinus rhythm will also increase LV diastolic filling time in patients with CHF and normal LV ejection fraction.

About this research paper

What this paper is about

Coronary artery disease, hypertension, valvular heart disease, and cardiomyopathies are the commonest causes of CHF in elderly patients. Almost half of elderly patients with CHF have normal LV ejection fraction. LV ejection fraction must be measured before knowing how to treat CHF. Underlying causes of CHF should be treated when possible. Precipitating causes of CHF should be treated. Diuretics are the first-line drug in the treatment of CHF. ACE inhibitors reduce mortality in patients with CHF and should be administered with diuretics to patients with CHF and abnormal or normal LV ejection fraction. Oral isosorbide dinitrate plus hydralazine improves survival in patients with CHF, and should be administered to patients with CHF and abnormal or normal LV ejection fraction who cannot tolerate ACE inhibitor therapy or in whom CHF persists despite therapy with diuretics plus ACE inhibitors. Digoxin should be administered to patients with a rapid ventricular rate associated with supraventricular tachyarrhythmias. Digoxin should be administered to patients with CHF in sinus rhythm and abnormal LV ejection fraction that does not respond to diuretics plus ACE inhibitors or in patients unable to tolerate ACE inhibitors or other vasodilator therapy. Digoxin should not be given to patients with CHF in sinus rhythm with normal LV ejection fraction. Calcium channel blockers are contraindicated in patients with CHF and abnormal LV ejection fraction but may be used to treat CHF with normal LV ejection fraction. The use of beta blockers in the treatment of CHF with abnormal LV ejection fraction is experimental. However, beta blockers might improve clinical symptoms in patients with CHF and normal LV ejection fraction by slowing heart rate, thereby increasing LV diastolic filling time and increasing LV end-diastolic volume. Maintenance of sinus rhythm will also increase LV diastolic filling time in patients with CHF and normal LV ejection fraction.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Coronary artery disease, hypertension, valvular heart disease, and cardiomyopathies are the commonest causes of CHF in elderly patients. Almost half of elderly patients with CHF have normal LV ejection fraction. LV ejection fraction must be measured before knowing how to treat CHF. Underlying causes of CHF should be treated when possible. Precipitating causes of CHF should be treated. Diuretics are the first-line drug in the treatment of CHF. ACE inhibitors reduce mortality in patients with CHF and should be administered with diuretics to patients with CHF and abnormal or normal LV ejection fraction. Oral isosorbide dinitrate plus hydralazine improves survival in patients with CHF, and should be administered to patients with CHF and abnormal or normal LV ejection fraction who cannot tolerate ACE inhibitor therapy or in whom CHF persists despite therapy with diuretics plus ACE inhibitors. Digoxin should be administered to patients with a rapid ventricular rate associated with supraventricular tachyarrhythmias. Digoxin should be administered to patients with CHF in sinus rhythm and abnormal LV ejection fraction that does not respond to diuretics plus ACE inhibitors or in patients unable to tolerate ACE inhibitors or other vasodilator therapy. Digoxin should not be given to patients with CHF in sinus rhythm with normal LV ejection fraction. Calcium channel blockers are contraindicated in patients with CHF and abnormal LV ejection fraction but may be used to treat CHF with normal LV ejection fraction. The use of beta blockers in the treatment of CHF with abnormal LV ejection fraction is experimental. However, beta blockers might improve clinical symptoms in patients with CHF and normal LV ejection fraction by slowing heart rate, thereby increasing LV diastolic filling time and increasing LV end-diastolic volume. Maintenance of sinus rhythm will also increase LV diastolic filling time in patients with CHF and normal LV ejection fraction.

Key concepts: Medicine, Ejection fraction, Heart failure, Digoxin, Cardiology, Internal medicine, Isosorbide dinitrate, Sinus rhythm

Related papers

Back to paper searchBrowse research topicsOriginal source
Management of congestive heart failure in the elderly patient. — Research Paper | ScholarLens